The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …

Objectives Obesity is associated with increased risks of atrial fibrillation (AF) and venous
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …

abstract The class of new oral anticoagulants (NOACs) has been developed to provide
reliable oral anticoagulation without the need for therapeutic drug monitoring. Based on …

Background Current evidence suggests that rivaroxaban may be well tolerated and effective
in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited …

Background Patients with atrial fibrillation and bioprosthetic valves are at high risk for
thromboembolic events. The pooled efficacy and safety of non-vitamin K oral anticoagulants …

Aims To compare clinical outcomes of rivaroxaban and warfarin in patients with nonvalvular
atrial fibrillation (NVAF) and concurrent obesity and diabetes. Methods Patients aged≥ 18 …

Introduction Direct oral anticoagulant (DOAC) agents are established as the anticoagulation
strategy of choice for a variety of clinical risks. Despite this, uncertainty still exists with regard …

Introduction oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of
choice for most clinical risks for which they are indicated. However, residual uncertainty …

Background Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-
line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently …

Abstract Introduction Direct oral anticoagulants (DOACs) are widely employed for
antithrombotic prophylaxis in patients with atrial fibrillation (AF). However, there is still …